ALAlexis Laux-Biehlmann

Alexis Laux-Biehlmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexis Laux-Biehlmann has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Yannick Goumon

    Institut des Neurosciences Cellulaires et Intégratives Université de Strasbourg, CNRS Strasbourg France

    13 shared publications
  • Alain Van Dorsselaer

    CNRS UMR7178, Laboratoire de Spectrométrie de Masse BioOrganique, IPHC-DSA, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg, France

    7 shared publications
  • François Delalande

    Laboratoire de spectrométrie de masse BioOrganique, IPHC-DSA, Université de Strasbourg, CNRS UMR7178, 25 rue Becquerel, Strasbourg, France

    6 shared publications
  • Pierrick Poisbeau

    University of Strasbourg, Centre National de la Recherche Scientifique, Cognitive and Adaptive Neuroscience Laboratory, Strasbourg, France

    6 shared publications
  • Jinane Mouheiche

    CNRS UPR3212, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg, France

    5 shared publications
  • Denise Stuber

    CNRS UPR3212, Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique and University of Strasbourg, Strasbourg, France

    3 shared publications

Latest Publications

  • Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor

    by Gernot Langer, John Scott, Christoffer Lind, Christiane Otto, Ulrich Bothe, Alexis Laux-Biehlmann, Jörg Müller, Beau le Roy, Horst Irlbacher, Katrin Nowak-Reppel, et al.

    The human pituitary adenylate cyclase activating polypeptide receptor (hPAC1-R), a class B GPCR identified almost 30 years ago, represents an important pharmacological target in the areas of neuroscience, oncology, and immunology. Despite interest in this target, only a very limited number of small molecule modulators have been reported for this receptor. We herein describe the results of a drug discovery program aiming for the identification of a potent and selective hPAC1-R antagonist. An initial HTS screen of 3.05 million compounds originating from the Bayer screening library failed to identify any tractable hits. A second, completely revised screen using native HEK293 cells yielded a small number of hits exhibiting antagonistic properties (4.2 million compounds screened). BAY 2686013 (1) emerged as a promising compound showing selective antagonistic activity in the sub-micromolar potency range. In depth characterization supported the hypothesis that BAY 2686013 blocks receptor activity in a non-competitive manner. Preclinical, pharmacokinetic profiling indicates that BAY 2686013 is a valuable tool compound for better understanding the signalling and function of hPAC1-R. Significance Statement Although the human PAC1-R is of major significance as a therapeutic target with a well-documented role in pain signaling, only a very limited number of small molecule (SMOL) compounds are known to modulate its activity. We identified and thoroughly characterized a novel, potent and selective SMOL antagonist of hPAC1-R (acting in an allosteric manner). These characteristics make BAY 2686013 an ideal tool for further studies.


  • Open Access

    Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain

    by Paulina Nunez-Badinez, Bianca De Leo, Alexis Laux-Biehlmann, Anja Hoffmann, Thomas M. Zollner, Philippa T.K. Saunders, Ioannis Simitsidellis, Ana Charrua, Francisco Cruz, Raul Gomez, et al.

    Endometriosis (ENDO) and interstitial cystitis/bladder pain syndrome (IC/BPS) are chronic pain conditions for which better treatments are urgently needed. Development of new therapies with proven clinical benefit has been slow. We have conducted a review of existing preclinical in vivo models for ENDO and IC/BPS in rodents, discussed to what extent they replicate the phenotype and pain experience of patients, as well as their relevance for translational research. In 1009 publications detailing ENDO models, 41% used autologous, 26% syngeneic, 18% xenograft, and 11% allogeneic tissue in transplantation models. Intraperitoneal injection of endometrial tissue was the subcategory with the highest construct validity score for translational research. From 1055 IC/BPS publications, most interventions were bladder-centric (85%), followed by complex mechanisms (8%) and stress-induced models (7%). Within these categories, the most frequently used models were instillation of irritants (92%), autoimmune (43%), and water avoidance stress (39%), respectively. Notably, although pelvic pain is a hallmark of both conditions and a key endpoint for development of novel therapies, only a small proportion of the studies (models of ENDO: 0.5-12%, models of IC/BPS: 20-44%) examined endpoints associated with pain. Moreover, only 2% and 3% of publications using models of ENDO and IC/BPS investigated non-evoked pain endpoints. This analysis highlights the wide variety of models used, limiting reproducibility and translation of results. We recommend refining models so that they better reflect clinical reality, sharing protocols, and employing standardized endpoints to improve reproducibility. We are addressing this in our project IMI-PainCare/Translational Research in Pelvic Pain (TRiPP).


  • Open Access

    Stable isotope‐labelled morphine to study in vivo central and peripheral morphine glucuronidation and brain transport in tolerant mice

    by Ivan Weinsanto, Alexis Laux‐Biehlmann, Jinane Mouheiche, Tando Maduna, François Delalande, Virginie Chavant, Florian Gabel, Pascal Darbon, Alexandre Charlet, Pierrick Poisbeau, et al.

    Background and Purpose: Chronic administration of medication can significantly affect metabolic enzymes leading to physiological adaptations. Morphine metabolism in the liver has been extensively studied following acute morphine treatment, but such metabolic processes in the CNS are poorly characterized. Long‐term morphine treatment is limited by the development of tolerance, resulting in a decrease of its analgesic effect. Whether or not morphine analgesic tolerance affects in vivo brain morphine metabolism and blood–brain barrier (BBB) permeability remains a major question. Here, we have attempted to characterize the in vivo metabolism and BBB permeability of morphine after long‐term treatment, at both central and peripheral levels.Experimental Approach: Male C57BL/6 mice were injected with morphine or saline solution for eight consecutive days in order to induce morphine analgesic tolerance. On the ninth day, both groups received a final injection of morphine (85%) and d3‐morphine (morphine bearing three 2H; 15%, w/w). Mice were then killed and blood, urine, brain and liver samples were collected. LC–MS/MS was used to quantify morphine, its metabolite morphine‐3‐glucuronide (M3G) and their respective d3‐labelled forms.Key Results: We found no significant differences in morphine CNS uptake and metabolism between control and tolerant mice. Interestingly, d3‐morphine metabolism was decreased compared to morphine without any interference with our study.Conclusions and Implications: Our data suggests that tolerance to the analgesic effects of morphine is not linked to increased glucuronidation to M3G or to altered global BBB permeability of morphine.


  • Open Access

    Lithium reverses mechanical allodynia through a mu opioid-dependent mechanism

    by Ivan Weinsanto, Jinane Mouheiche, Alexis Laux-Biehlmann, Maya Aouad, Tando Maduna, Nathalie Petit-Demoulière, Virginie Chavant, Pierrick Poisbeau, Pascal Darbon, Alexandre Charlet, et al.

    Background: Lithium is widely used to treat bipolar disorders and displays mood stabilizing properties. In addition, lithium relieves painful cluster headaches and has a strong analgesic effect in neuropathic pain rat models.Objectives: To investigate the analgesic effect of lithium on the cuff model of neuropathic pain.Methods: We used behavioral and pharmacological approaches to study the analgesic effect of a single injection of lithium in wild-type and mu opioid receptor (MOR) null cuffed neuropathic mice. Mass spectrometry and enzyme-linked immunosorbent assay allowed to measure the levels of endogenous MOR agonist beta-endorphin as well as monoamines in brain and plasma samples 4 h after lithium administration.Results: A single injection of lithium chloride (100 mg/kg, ip) alleviated mechanical allodynia for 24 h, and this effect was absent in MOR null neuropathic mice. Biochemical analyses highlight a significant increase in beta-endorphin levels by 30% in the brain of lithium-treated mice compared to controls. No variation of beta-endorphin was detected in the blood.Conclusions: Together, our results provide evidence that lithium induces a long-lasting analgesia in neuropathic mice presumably through elevated brain levels of beta-endorphin and the activation of MORs.


  • Dynamic weight bearing as a non‐reflexive method for the measurement of abdominal pain in mice

    by A. Laux‐Biehlmann, J. Boyken, H. Dahllöf, N. Schmidt, T.M. Zollner, J. Nagel

    Background: Chronic pelvic pain (CPP) is a high burden for patients and society. It affects 15–24% of women in reproductive age and is an area of high unmet medical need. CPP can be caused by a wide range of visceral diseases such as abdominal infections, gastrointestinal or gynaecological diseases like endometriosis. Despite the high medical need for this condition, pharmacological approaches are hampered by the limited number of available methods for the behavioural evaluation of pain in inflammation‐driven animal models of pelvic pain.Methods: The dynamic weight bearing (DWB) system was used for the evaluation of spontaneous behaviour changes in the zymosan‐induced peritonitis mouse model. Inflammatory mediator levels were evaluated in peritoneal lavage and their correlation with the behavioural endpoints was assessed. We evaluated the effect on behavioural endpoints of the selective cyclooxygenase‐2 (COX‐2) inhibitor celecoxib and the Nav1.8 blocker A‐803467.Results: The presence of a relief posture, characterized by a significantly increased weight distribution towards the front paws, was observed following intraperitoneal injection of zymosan. A positive correlation was detected between PGE2 levels in the peritoneal lavage and DWB endpoints. In addition, zymosan‐induced weight bearing changes were reverted by celecoxib and A‐803467.Conclusions: This study described for the first time the use of DWB as a non‐subjective and non‐reflexive method for the evaluation of inflammatory‐driven abdominal pain in a mouse model.


  • Menstruation pulls the trigger for inflammation and pain in endometriosis

    by Alexis Laux-Biehlmann, Thomas D’hooghe, Thomas M. Zollner


  • Open Access

    Defective response inhibition and collicular noradrenaline enrichment in mice with duplicated retinotopic map in the superior colliculus

    by Chantal Mathis, Elise Savier, Jean-Bastien Bott, Daniel Clesse, Nicholas Bevins, Dominique Sage-Ciocca, Karin Geiger, Anaïs Gillet, Alexis Laux-Biehlmann, Yannick Goumon, et al.

    The superior colliculus is a hub for multisensory integration necessary for visuo-spatial orientation, control of gaze movements and attention. The multiple functions of the superior colliculus have prompted hypotheses about its involvement in neuropsychiatric conditions, but to date, this topic has not been addressed experimentally. We describe experiments on genetically modified mice, the Isl2-EphA3 knock-in line, that show a well-characterized duplication of the retino-collicular and cortico-collicular axonal projections leading to hyperstimulation of the superior colliculus. To explore the functional impact of collicular hyperstimulation, we compared the performance of homozygous knock-in, heterozygous knock-in and wild-type mice in several behavioral tasks requiring collicular activity. The light/dark box test and Go/No-Go conditioning task revealed that homozygous mutant mice exhibit defective response inhibition, a form of impulsivity. This defect was specific to attention as other tests showed no differences in visually driven behavior, motivation, visuo-spatial learning and sensorimotor abilities among the different groups of mice. Monoamine quantification and gene expression profiling demonstrated a specific enrichment of noradrenaline only in the superficial layers of the superior colliculus of Isl2-EphA3 knock-in mice, where the retinotopy is duplicated, whereas transcript levels of receptors, transporters and metabolic enzymes of the monoaminergic pathway were not affected. We demonstrate that the defect in response inhibition is a consequence of noradrenaline imbalance in the superficial layers of the superior colliculus caused by retinotopic map duplication. Our results suggest that structural abnormalities in the superior colliculus can cause defective response inhibition, a key feature of attention-deficit disorders.


  • Endogenous morphine‐6‐glucuronide (M6G) is present in the plasma of patients: Validation of a specific anti‐M6G antibody for clinical and basic research

    by Alexis Laux‐Biehlmann, Hélène Chung, Jinane Mouheiche, Julie Vérièpe, François Delalande, Marc Lamshöft, Ingeborg D. Welters, Stéphanie Soldevila, Hervé Bazin, Laurent Lamarque, et al.

    Endogenous morphine and its derivatives (morphine‐6‐glucuronide [M6G]; morphine‐3‐glucuronide [M3G]) are formed by mammalian cells from dopamine. Changes in the concentrations of endogenous morphine have been demonstrated in several pathologies (sepsis, Parkinson's disease, etc.), and they might be relevant as pathological markers. While endogenous morphine levels are detectable using enzyme‐linked immunosorbant assay (ELISA), mass spectrometry (MS) analysis was, so far, the only approach to detect and quantify M6G. This study describes the preparation of a specific anti‐M6G rabbit polyclonal antibody and its validation. The specificity of this antibody was assessed against 30 morphine‐related compounds. Then, a M6G‐specific ELISA‐assay was tested to quantify M6G in the plasma of healthy donors, morphine‐treated, and critically ill patients. The antibody raised against M6G displays a strong affinity for M6G, codeine‐6‐glucuronide, and morphine‐3‐6‐glucuronide, whereas only weak cross‐reactivities were observed for the other compounds. Both M6G‐ELISA and LC‐MS/MS approaches revealed the absence of M6G in the plasma of healthy donors (controls, n = 8). In all positive donors treated with morphine‐patch (n = 5), M6G was detected using both M6G‐ELISA and LC‐MS/MS analysis. Finally, in a study on critically ill patients with circulating endogenous morphine (n = 26), LC‐MS/MS analysis revealed that 73% of the positive‐patients (19 of 26), corresponding to high M6G‐levels in M6G‐ELISA, contained M6G. In conclusion, we show that endogenous M6G can be found at higher levels than morphine in the blood of morphine‐naive patients. With respect to the interest of measuring endogenous M6G in pathologies, we provide evidences that our ELISA procedure represents a powerful tool as it can easily and specifically detect endogenous M6G levels. © 2013 BioFactors, 40(1):113–120, 2014